373 related articles for article (PubMed ID: 18612114)
1. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
[TBL] [Abstract][Full Text] [Related]
2. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
Potosky AL; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Jiang M; Tsai HT; Luta G; Keating NL; Smith MR; Van Den Eeden SK
J Clin Oncol; 2014 May; 32(13):1324-30. PubMed ID: 24638009
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
7. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
[TBL] [Abstract][Full Text] [Related]
8. Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?
Lu-Yao GL; Albertsen PC; Li H; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2012 Dec; 62(6):966-72. PubMed ID: 22608160
[TBL] [Abstract][Full Text] [Related]
9. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
Royce TJ; Chen MH; Wu J; Loffredo M; Renshaw AA; Kantoff PW; D'Amico AV
JAMA Oncol; 2017 May; 3(5):652-658. PubMed ID: 28097317
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
[TBL] [Abstract][Full Text] [Related]
11. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
[TBL] [Abstract][Full Text] [Related]
12. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
13. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
Hori S; Jabbar T; Kachroo N; Vasconcelos JC; Robson CN; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2011 Feb; 137(2):235-41. PubMed ID: 20390426
[TBL] [Abstract][Full Text] [Related]
15. Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer.
Dell'Oglio P; Boehm K; Trudeau V; Tian Z; Larcher A; Leyh-Bannurah SR; Moschini M; Capitanio U; Shariat SF; Briganti A; Montorsi F; Saad F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1037-1045. PubMed ID: 27478167
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
Bekelman JE; Mitra N; Handorf EA; Uzzo RG; Hahn SA; Polsky D; Armstrong K
J Clin Oncol; 2015 Mar; 33(7):716-22. PubMed ID: 25559808
[TBL] [Abstract][Full Text] [Related]
17. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
19. Reduction in physician reimbursement and use of hormone therapy in prostate cancer.
Elliott SP; Jarosek SL; Wilt TJ; Virnig BA
J Natl Cancer Inst; 2010 Dec; 102(24):1826-34. PubMed ID: 21131577
[TBL] [Abstract][Full Text] [Related]
20. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]